Personalized Deep Brain Stimulation for Refractory Epilepsy Shows Promise
Researchers at Mayo Clinic have developed and begun implementing a novel, personalized approach to deep brain stimulation (DBS) for individuals living with drug-resistant epilepsy. This innovative method moves beyond the conventional one-size-fits-all paradigm by meticulously mapping each patient’s unique brain wave patterns, thereby enabling clinicians to precisely target the most effective region for stimulation. This advancement holds significant implications for patients who do not respond to traditional antiepileptic medications.
Deep brain stimulation involves surgically implanting electrodes within the brain to deliver controlled electrical pulses, aiming to prevent and manage seizures. While DBS has been an established treatment for epilepsy, its application has historically involved placing electrodes in a standardized brain region across most patients. The Mayo Clinic physician-scientists are now leveraging an individualized strategy, tailoring the treatment to target a person’s specific seizure network before DBS lead placement, offering a more refined interventional approach. This shift towards personalized neuromodulation represents a crucial step in optimizing outcomes for patients with intractable epilepsy.
According to Dr. Nick Gregg, a Mayo Clinic neurologist and lead author of a study published in the Annals of Neurology, “Our unique approach aims to tailor neuromodulation for each patient. We’re moving away from one-size-fits-all to an individualized approach that maximizes seizure network engagement to better modulate abnormal brain wave activity.” This method helps to identify the precise area within the thalamus, a critical relay hub deep inside the brain, that is most intricately connected to a patient’s seizure network. Once this connection is established, stimulation settings can be fine-tuned to the individual’s physiological needs. Given that seizures are often intermittent, clinicians analyze erratic brain wave patterns, known as interictal epileptiform discharges, which serve as crucial indicators of underlying abnormal brain activity.
Dr. Gregg further elaborated on the therapeutic goal, stating, “We’re trying to disrupt the pathological hypersynchrony and reduce network excitability to lower seizure risk.” This targeted disruption aims to quiet the hyperactive neuronal networks responsible for generating seizures. The initial phase of this personalized approach enrolled ten patients who were undergoing evaluation for epilepsy surgery. The subsequent research phase will involve tracking the progress of these patients who have received permanent DBS implants based on this advanced, personalized mapping technique.
Future Implications and Broader Health Context
The long-term vision for this research extends beyond mere seizure control. Dr. Gregg expressed optimism that “The long-term goal is to quiet the seizure network, so it is eventually forgotten. Reorganizing the neuronal network could move us beyond controlling seizures to actually curing epilepsy.” This ambitious objective underscores the transformative potential of personalized neuromodulation in the field of neurology. This research is an integral part of Mayo Clinic’s Bioelectronic Neuromodulation Innovation to Cure (BIONIC) initiative, which synergizes clinical expertise with cutting-edge engineering to develop novel diagnostics and therapeutics for complex neurological conditions. Through robust intellectual property development, strategic collaborations, and patient-centered clinical trials, the BIONIC initiative aims to translate innovative concepts into tangible improvements in patient care.
The development of personalized treatments like this for epilepsy highlights a broader trend in medicine towards precision health, where therapies are customized based on individual biological and genetic characteristics. This is particularly relevant in conditions like epilepsy, which can manifest with significant variability among patients. While the World Health Organization (WHO) continues to track global health challenges, including neurological disorders, advancements in personalized medicine offer new hope for debilitating conditions. For instance, the WHO’s Global antibiotic resistance surveillance report 2025 emphasizes the ongoing need for innovative solutions in healthcare, illustrating a broader commitment to scientific progress in various medical fields.
Drug-resistant epilepsy affects a significant number of individuals worldwide, leading to a substantial burden on quality of life, mental health, and healthcare systems. Conditions such as epilepsy can sometimes co-occur with or be exacerbated by other health factors, including infectious diseases. For example, recent reports, such as the scoping review on Mpox published in PMC, demonstrate the ongoing need for research into emerging pathogens and their broader health impacts. Addressing complex neurological conditions with personalized therapies helps to reduce the overall health burden and improve patient outcomes globally. Read more on Globally Pulse Health.
